UK markets closed

180 Life Sciences Corp. (ATNF)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.6200-0.0500 (-2.99%)
At close: 04:00PM EDT
1.7000 +0.08 (+4.94%)
After hours: 06:14PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.6700
Open1.6800
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.6102 - 1.7800
52-week range1.3300 - 26.0300
Volume52,937
Avg. volume179,567
Market cap1.525M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-30.1200
Earnings date13 Aug 2024 - 19 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

    PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As indicated in the letter, Nasdaq determined that for 1

  • GlobeNewswire

    180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

    PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted

  • GlobeNewswire

    180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

    PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include, but are not limited to, an acquisition, merger, reverse merger, other business combination,